Silence Therapeutics plc (FRA:XRP2)

Silence Therapeutics Statistics

Total Valuation

FRA:XRP2 has a market cap or net worth of EUR 267.76 million. The enterprise value is 180.01 million.

Market Cap	267.76M
Enterprise Value	180.01M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+7.98%
Shares Change (QoQ)	-1.39%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	24.92M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.16
PB Ratio	4.24
P/TBV Ratio	4.97
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.27
EV / Sales	8.10
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.91

Financial Position

The company has a current ratio of 7.69, with a Debt / Equity ratio of 0.00.

Current Ratio	7.69
Quick Ratio	7.16
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	-0.00
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -64.30% and return on invested capital (ROIC) is -43.50%.

Return on Equity (ROE)	-64.30%
Return on Assets (ROA)	-23.40%
Return on Invested Capital (ROIC)	-43.50%
Return on Capital Employed (ROCE)	-54.08%
Revenue Per Employee	189,784
Profits Per Employee	-474,202
Employee Count	116
Asset Turnover	0.14
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:XRP2 has paid 285,521 in taxes.

Income Tax	285,521
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -19.29% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-19.29%
50-Day Moving Average	5.18
200-Day Moving Average	4.28
Relative Strength Index (RSI)	51.75
Average Volume (20 Days)	69

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.01

Income Statement

In the last 12 months, FRA:XRP2 had revenue of EUR 22.01 million and -55.01 million in losses. Loss per share was -1.16.

Revenue	22.01M
Gross Profit	20.10M
Operating Income	-59.65M
Pretax Income	-54.72M
Net Income	-55.01M
EBITDA	-59.15M
EBIT	-59.65M
Loss Per Share	-1.16

Balance Sheet

The company has 87.10 million in cash and 155,119 in debt, giving a net cash position of 86.94 million.

Cash & Cash Equivalents	87.10M
Total Debt	155,119
Net Cash	86.94M
Net Cash Per Share	n/a
Equity (Book Value)	63.12M
Book Value Per Share	1.34
Working Capital	99.08M

Cash Flow

In the last 12 months, operating cash flow was -61.76 million and capital expenditures -99,719, giving a free cash flow of -61.86 million.

Operating Cash Flow	-61.76M
Capital Expenditures	-99,719
Free Cash Flow	-61.86M
FCF Per Share	n/a

Margins

Gross margin is 91.32%, with operating and profit margins of -270.95% and -249.86%.

Gross Margin	91.32%
Operating Margin	-270.95%
Pretax Margin	-248.57%
Profit Margin	-249.86%
EBITDA Margin	-268.70%
EBIT Margin	-270.95%
FCF Margin	n/a

Dividends & Yields

FRA:XRP2 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-7.98%
Shareholder Yield	-7.98%
Earnings Yield	-20.54%
FCF Yield	-23.10%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:XRP2 has an Altman Z-Score of -3 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-3
Piotroski F-Score	2